← Back to Clinical Trials
Recruiting NCT04104529

NCT04104529 Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04104529
Status Recruiting
Phase
Sponsor Institut du Cancer de Montpellier - Val d'Aurelle
Condition Thyroid Cancer
Study Type INTERVENTIONAL
Enrollment 350 participants
Start Date 2019-10-28
Primary Completion 2026-10

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Biological collectiontumor collection

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 350 participants in total. It began in 2019-10-28 with a primary completion date of 2026-10.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Development of a clinico-biological database allowing the provision of clinical data and corresponding biological materials to the medical and scientific community.

Eligibility Criteria

Inclusion Criteria: * Age ≥ at 18 years old, * Patient treated in the Nuclear Medicine Department for the treatment by metabolic radiotherapy, * Patient treated as part of his treatment for: * thyroid cancer, * a neuroendocrine tumor or * prostate cancer. * Patient having accepted the complementary blood sample, * Patient having given his informed, written and express consent. Exclusion Criteria: * Patient not affiliated to a social security scheme, * Subject under tutelage, curatorship or safeguard of justice, * Patient in an emergency situation * Patient whose regular monitoring is a priori impossible for psychological, family, social or geographical reasons, * Pregnant and / or breastfeeding woman

Contact & Investigator

Central Contact

Aurore MOUSSION

✉ DRCI-icm105@icm.unicancer.fr

📞 0467613102

Principal Investigator

Emmanuel DESHAYES, MD

STUDY CHAIR

Institut régional du Cancer Montpellier

Frequently Asked Questions

Who can join the NCT04104529 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Thyroid Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04104529 currently recruiting?

Yes, NCT04104529 is actively recruiting participants. Contact the research team at DRCI-icm105@icm.unicancer.fr for enrollment information.

Where is the NCT04104529 trial being conducted?

This trial is being conducted at Bordeaux, France, Marseille, France, Montpellier, France, Toulouse, France.

Who is sponsoring the NCT04104529 clinical trial?

NCT04104529 is sponsored by Institut du Cancer de Montpellier - Val d'Aurelle. The principal investigator is Emmanuel DESHAYES, MD at Institut régional du Cancer Montpellier. The trial plans to enroll 350 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology